The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer

Molecular Diagnosis and Therapy

Volumn 13, Issue 5, 2009, Pages 277-281

  Ramsey, Sara ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB;

HEART INFARCTION; HUMAN; IMMUNOTHERAPY; KIDNEY CANCER; KIDNEY METASTASIS; NEPHRECTOMY; NOTE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; QUALITY OF LIFE; RESPIRATORY FAILURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 70349677449     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256333     Document Type: Note

References (34)

1. Dorr RT. Interferon-a in malignant and viral disease. Drugs 1993; 45 (2): 177-211
2. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: a randomized trial. Acta Oncol 1990; 29 (2): 155-162
3. Kreigmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995; 45 (5): 758-762
4. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17 (9): 2859-2867
5. Medical Research Council Renal Cancer Collaborators. Interferon-a and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353: 14-17
6. Coppin A, Porzolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425
7. Mickisch GHJ, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358 (9286): 966-970
8. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345 (23): 1655-1659
9. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who receive high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696
10. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003 Aug 15; 21 (16): 3127-3132
11. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23 (1): 133-141
12. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 7310-7313
13. Biomarkers Definitions WorkingGroup. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655
15. Motzer RJ, Mazumdar M, Baik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540
16. Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460-1468
17. Ando M, Ando Y, Hasegawa Y, et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced nonsmall cell lung cancer. Br J Cancer 2001; 85: 1634-1639
18. Bui MHT, Seligson D, Han K, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811
19. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11 (10): 3714-3721
20. Shuch B, Li Z, Belldegrun AS. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. BJU Int 2008; 101 Suppl. 4: 25-30
21. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340 (6): 448-454
22. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279 (47): 48487-48490
23. Crumley AB, McMillan DC, McKernan M, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable gastrooesophageal cancer. Br J Cancer 2006; 94 (5): 637-641
24. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007; 97 (9): 1266-1270
25. Glen P, Jamieson NB, McMillan DC, et al. Evaluation of an inflammationbased prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006; 6 (5): 450-453
26. Forrest LM, McMillan DC, McArdle CS, et al. Comparison of an inflammation- based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004; 90 (9): 1704-1706
27. Al Murri AM, Bartlett JM, Canney PA, et al. Evaluation of an inflammationbased prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006; 94 (2): 227-230
28. Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammationbased prognostic score in patients with metastatic renal cancer. Cancer 2007; 109 (2): 205-212
29. Bromwich E, McMillan DC, Lamb GW, et al. The systemic inflammatory response, performance status and survival in patients undergoing alphainterferon treatment for advanced renal cancer. Br J Cancer 2004; 91 (7): 1236-1238
30. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005; 173 (1): 52-55
31. Miyake H, Kurahashi T, Takenaka A, et al. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol. Epub 2008 Sep 23
32. Tatokoro M, Saito K, Iimura Y, et al. Prognostic impact of postoperative Creactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 2008; 180 (2): 515-519
33. Ramsey S, AitchisonM,Graham J, et al. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer. BJU Int 2008; 102 (1): 125-129
34. Saito K, Tatokoro M, Fujii Y, et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. EurUrol. Epub 2008 Oct 14